Evaluation of DNAJB1-PRKACA Fusion Transcript-Based Peptide Vaccine and Immune Checkpoint Inhibition in Fibrolamellar Hepatocellular Carcinoma and Oncogenic Driver Fusion Tumors

The primary objective of the study titled "FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion" is not explicitly stated. However, the study focuses on evaluating the efficacy of a **DNAJB1-PRKACA** fusion transcript-based peptide vaccine in combination with immune checkpoint inhibitors. This approach targets **fibrolamellar hepatocellular carcinoma** and other tumors with the oncogenic driver fusion, aiming to enhance the immune response against these malignancies. The clinical relevance lies in potentially offering a novel therapeutic strategy for these specific cancer types, which are often challenging to treat with conventional therapies.

The clinical trial involves participants diagnosed with **fibrolamellar hepatocellular carcinoma** or other tumor entities carrying the oncogenic driver fusion DNAJB1-PRKACA. The study population includes both male and female subjects, with an age range encompassing adolescents and adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or the selection process for the trial population. No specific lifestyle considerations such as diet, physical activity, or habits have been highlighted for this study.

The clinical trial is designed to evaluate the efficacy and safety of a **DNAJB1-PRKACA** fusion transcript-based peptide vaccine in combination with immune checkpoint inhibition for the treatment of **fibrolamellar hepatocellular carcinoma** and other tumor entities carrying the oncogenic driver fusion. This trial is structured as a Phase 1 study, which is typically the initial phase in clinical research aimed at assessing the safety, tolerability, and optimal dosing of a new therapeutic intervention. The trial is expected to commence recruitment on August 1, 2023, and is projected to conclude by January 31, 2027.

The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group receiving the investigational vaccine and immune checkpoint inhibitors or a control group. The double-blind nature of the study ensures that neither the participants nor the investigators are aware of the group assignments, thereby minimizing bias.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits to monitor their response to the treatment and any potential adverse effects. These visits will include comprehensive assessments such as physical examinations, laboratory tests, and imaging studies as necessary. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to assess the overall outcomes of the intervention.

The expected duration of participant involvement in the trial will vary depending on individual response and the specific protocol requirements. However, participants should anticipate being involved for the entirety of the trial period unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent, or any other protocol-defined criteria that warrant discontinuation from the study.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental medication's maximum daily dose, maximum total dose, or maximum treatment period. Furthermore, there is no information regarding whether the medication is a **paediatric formulation** or an **orphan drug**. The trial's main objective and full title are also not provided in the data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is August 1, 2023, with an anticipated end date of January 31, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant biomarkers or clinical symptoms. The schedule for measuring and collecting efficacy data is typically aligned with the trial's protocol, ensuring systematic data collection at predefined timepoints throughout the study duration. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the efficacy assessments.